TABLE 1.
Demographics of respondents with alopecia areata after COVID‐19 infection or vaccination
| Percentage of completed questionnaires (n = 131) | 131/214 (61.2%) |
| Mean age of respondents (SD) (years) | 41.6 (14.8) |
| Mean age at diagnosis of AA (SD) (years) | 33.5 (12.2) |
| Female | 115/131 (87.8%) |
| Ethnicity | |
| White | 93/131 (71.0%) |
| Asian | 12/131 (9.2%) |
| Hispanic or Latino | 7/131 (5.3%) |
| Black or African American | 3/131 (2.3%) |
| Native Hawaiian or Other Pacific Islander | 1/131 (0.7%) |
| Two or More or Other | 12/131 (9.2%) |
| Prefer not to say | 3/131 (2.3%) |
| Treatments utilized, where reported (n = 48) a | |
| Corticosteroid injection | 20/48 (41.7%) |
| Topical corticosteroid | 18/48 (37.5%) |
| Oral corticosteroid | 4/48 (8.3%) |
| Corticosteroid (unspecified mode of delivery) | 1/48 (2.1%) |
| Oral or topical minoxidil | 11/48 (22.9%) |
| Oral JAK inhibitor | 5/48 (10.4%) |
| Topical JAK inhibitor | 3/48 (6.3%) |
| JAK inhibitor (unspecified mode of delivery) | 1/48 (2.1%) |
| Oral antihistamine | 1/48 (2.1%) |
| Mycophenolate mofetil injection | 1/48 (2.1%) |
| Oral hydroxychloroquine | 1/48 (2.1%) |
| No treatment | 2/48 (4.2%) |
Abbreviations: AA, alopecia areata; JAK, Janus kinase; SD, standard deviation.
a
Participants were able to specify more than one treatment.